Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments

Area of Science:

• Pediatric Oncology
• Hematology
• Cancer Biology

Background:

• Relapsed acute lymphoblastic leukemia (ALL) is a significant cause of pediatric mortality.
• While survival for newly diagnosed ALL exceeds 85%, approximately 20% of patients relapse, facing poor prognoses.
• Maintaining remission after achieving a second complete remission in relapsed ALL remains a challenge.

Purpose of the Study:

• To review the current understanding of relapsed acute lymphoblastic leukemia (ALL) in pediatric patients.
• To discuss the underlying biology driving relapse and its impact on treatment strategies.
• To explore emerging therapeutic approaches and prognostic factors for relapsed ALL.

Main Methods:

• Literature review focusing on relapsed acute lymphoblastic leukemia (ALL) in pediatrics.
• Analysis of current treatment protocols, including chemotherapy, hematopoietic stem cell transplantation, and novel agents.
• Discussion of prognostic indicators and the biological mechanisms of ALL relapse.

Main Results:

• Outcomes for pediatric patients with relapsed ALL remain poor despite intensive chemotherapy.
• Hematopoietic stem cell transplantation is often considered for high-risk patients due to limited efficacy of conventional chemotherapy alone.
• New drug classes with minimal cross-resistance are under investigation for relapsed ALL treatment.

Conclusions:

• Relapsed ALL in children necessitates continued research into its biology and treatment.
• Novel therapeutic agents and a refined role for hematopoietic stem cell transplantation are crucial for improving outcomes.
• Understanding prognostic factors is essential for tailoring treatment strategies in relapsed pediatric ALL.